Patients with moderate to severe dorsal hand skin deterioration (score equal or more than 3 on the Hand Volume Rating Scale [HVRS]). hand rejuvenation, hyaluronic acid
Conditions
Interventions
combined of high, medium and low molecular weight hyaluronic acid injection for hand rejuvenation
Experimental Drug
Sponsors
Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
Eligibility
Sex/Gender
All
Age
30 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Adults aged 30-60 years, both male and female. 2. Participants with moderate to severe dorsal hand skin deterioration (score equal or more than 3 on the Hand Volume Rating Scale [HVRS]). 3. Participants of Thai ethnicity of Asian descent. 4. Participants who willingly consent to participate in the study and agree to receive filler injections in the specified amounts and treatment sites according to the research protocol.
Exclusion criteria
Exclusion criteria: 1.Pregnant or breastfeeding women. 2. Participants with a history of platelet disorders, coagulation abnormalities, anemia, liver disease, cancer, or immunodeficiency disorders. 3. Participants who smoke or have a history of heavy alcohol consumption defined as at least 30 pack years of smoking or more than 2 standard drinks per day or more than 5 days per week. One standard drink equals 10 grams of alcohol which is equal to one can of beer with alcohol content between 5 and 7 percent or three caps of whisky or white spirits with alcohol content between 40 and 43 percent or one glass of wine with alcohol content between 11 and 13 percent. 4. Participants with dermatitis, wounds, or active skin infection on the hands. 5. Participants with a history of allergy to local anesthetics. 6. Participants who regularly take hormones, contraceptives in oral or injectable form, or NSAIDs. 7. Participants who take medications that affect blood coagulation such as aspirin or anticoagulants. 8. Participants who have undergone hand skin tightening procedures including lifting devices within 6 months before enrollment. 9. Participants who have received dermal filler injections on the dorsal hands within 6 months before enrollment. 10. Participants who have received platelet rich plasma injections on the dorsal hands within 6 months before enrollment. 11. Participants who have received botulinum toxin injections on the dorsal hands within 6 months before enrollment. 12. Participants who have received collagen stimulating laser treatments on the dorsal hands including picosecond laser, erbium YAG laser, fractora, or laser E matrix within 6 months before enrollment. 13. Participants with a history of keloid formation. 14. Participants with psychiatric disorders diagnosed by a psychiatrist. 15. Participants who do not permit photography for treatment evaluation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Physician improvement scale Baseline, 1, 3, 6, 9 and 12 months after complete the treatment. Quartile scale,Patient improvement scale Baseline, 1, 3, 6, 9 and 12 months after complete the treatment Quartile scale | — |
Secondary
| Measure | Time frame |
|---|---|
| Skin elasticity Baseline, 1, 3, 6, 9 and 12 months after complete the treatment. Cutometer,Melanin and erythema index Baseline, 1, 3, 6, 9 and 12 months after complete the treatment. mexameter,Skin hydration Baseline, 1, 3, 6, 9 and 12 months after complete the treatment. corneometer,ITA index Baseline, 1, 3, 6, 9 and 12 months after complete the treatment. colorimeter,Average Wrinkle and Texture improvement Baseline, 1, 3, 6, 9 and 12 months after complete the treatment. Antera 3D,Volume analysis Baseline, 1, 3, 6, 9 and 12 months after complete the treatment. Quantificare and Vectra H2,Pain score Immediate Visual analog scale,Safety Immediate, 1, 3, 6, 9 and 12 months after complete the treatment. Adverse event | — |
Countries
Thailand
Contacts
Public ContactRungsima Wanitphakdeedecha
Faculty of Medicine Siriraj Hospital, Mahidol University
Outcome results
None listed